TELEXOS GMBH
Company Snapshot
Company Overview
Telexos GmbH, founded in 2016, is developing and commercializing products for the detection and analysis of rare cells in blood, including CTCs and rare immune cells.
Telexos is building its business around its unique workflow, which includes the following components:
- Isolation of CTCs as single cells.
- Analysis of protein or genomic markers in the same cell.
- Analysis of certain rare white blood cells (WBCs).
The overall workflow allows for detection of individual CTCs in a blood sample. Also, because the recovery yield of WBCs is 93% to 99%, the workflow permits analysis of certain rare WBCs.
Telexos is developing cancer-specific tests for both clinical research and diagnostic applications. For cancer research, Telexos markets kits to be used to generate insight into metastasis, new tumor markers and more. On the diagnostic side, the company’s kits can be used for early cancer detection, therapy guidance and monitoring of personalized therapy to assess the efficacy of the therapy and/or to detect dynamic changes at an early stage.
Company's Business Segments
- Clinical Research : The company provides cancer diagnostics and research services using a highly sensitive liquid biopsy technology to analyze rare cells like circulating tumor cells (CTCs) in blood samples.
Applications/End User Industries
- Cancer Diagnostics
- Personalized Medicine
- Clinical Cancer Research
- Therapy Monitoring
- Early Cancer Detection
- Drug Development